georgeclerk J.P. Morgan upgraded Solid Biosciences (NASDAQ:SLDB) from neutral to outperform, sending shares of the biotech up 10% Monday. The firm also raised its price target to $15 from $10 (~89% upside based on July 12 close). Analyst Anupam Rama believes that a recent label expansion for Sarepta Therapeutics’ (SRPT)Continue Reading
U.Today – JP Morgan CEO Jamie Dimon has issued a warning with consequences for the markets. This latest warning has left many investors wondering about the implications for various asset classes, particularly cryptocurrencies. According to CNBC, the JPMorgan CEO issued a warning about inflation on Friday despite recent signs ofContinue Reading
cagkansayin With Big Pharma $380B deal-making firepower, Morgan Stanley cites a favorable backdrop for biopharma M&A as key drugs in their portfolios face patent cliffs, risking as much as $180B in revenue. In a research note this week, Morgan Stanley analysts led by Terence Flynn listed large-cap drugmakers with theContinue Reading
aluxum United Therapeutics (NASDAQ:UTHR) traded lower on Thursday after Morgan Stanley downgraded the Tyvaso maker to Equal Weight from Overweight, citing a balanced risk-reward setup following strong gains this year. Morgan Stanley said that United Therapeutics (UTHR), which markets drugs for a lung disorder called pulmonary arterial hypertension (PAH), hasContinue Reading
adventtr Microchip Technology (NASDAQ:MCHP) and On Semiconductor (NASDAQ:ON) were downgraded by Morgan Stanley on Wednesday due to valuation concerns and issues related to the automotive industry. Shares fell 2% and 2.2% respectively, in extended trading. While Microchip has only gained 11% year-to-date, far below some of its peers, the valuationContinue Reading
Comstock Images/Stockbyte via Getty Images Ally Financial (NYSE:ALLY) stock perked up 2.3% in Monday morning trading after J.P. Morgan upgraded the auto lender to Neutral from Underweight as analyst Richard Shane thinks its credit, net interest margin and multiple trajectory “have been overly conservative.” “As the impact of less profitableContinue Reading
Drew Angerer/Getty Images News Morgan Stanley weighed in on NIO’s (NYSE:NIO) announcement from earlier on Friday that Chief Financial Officer Steven Wei Feng has resigned for personal reasons, to be replaced by Senior Vice President Stanley Yu Qu. Analyst Tim Hsiao noted that C-level change is rarely positive news, butContinue Reading
anatoliy_gleb/iStock via Getty Images J.P. Morgan (JPM) foresees an acceleration in demand for oil, as it expects a travel trend that emerged from the pandemic to keep running. In the firm’s 2024 mid-year outlook released last last week, its commodity analysts said they expected a seasonal uptick in oil demandContinue Reading
sutthirat sutthisumdang Morgan Stanley initiated coverage of Absci (NASDAQ:ABSI) with an overweight rating, noting it sees the stock as “an economical way of gaining exposure to the theme of AI in biotech/drug development.” The investment bank said it sees the stock’s risk-reward skewing to the upside ahead of catalysts andContinue Reading
ismagilov BofA and J.P. Morgan initiated coverage of newly public healthcare payments platform Waystar (NASDAQ:WAY) with bullish ratings, with BofA seeing the company benefitting from the recent cyberattack on rival UnitedHealth Group’s (UNH) Change Healthcare. BofA started coverage of Waystar with a buy rating, noting that the recent ransomware attackContinue Reading
